Notably, we found that the level of FSCN1+ tumor cells in tissue was 6.45-fold higher in HNSCC patients with relapses within one year after anticancer treatment compared with HNSCC patients without disease progression (P ˂ 0.05). Here, FSCN1 is linked to neoplasm.